It's listed right in that abstract. A total of
Post# of 148322
Quote:
A total of n = 68 TEAEs were reported, with n = 7 grade I/II & n = 1 grade III related to leronlimab.
7 treatment-emergent adverse events grade 1 & 2. 1 is mild ae, 2 is moderate ae. 1 treatment-emergent adverse events grade 3, Grade 3 is a severe ae.